Compare WIW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WIW | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.4M | 550.7M |
| IPO Year | N/A | 2024 |
| Metric | WIW | CTNM |
|---|---|---|
| Price | $7.93 | $8.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.14 |
| AVG Volume (30 Days) | 332.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-06-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.83 | $6.73 |
| 52 Week High | $8.95 | $17.79 |
| Indicator | WIW | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 32.94 |
| Support Level | $7.84 | $6.73 |
| Resistance Level | $8.00 | $13.72 |
| Average True Range (ATR) | 0.06 | 0.97 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 50.56 | 20.06 |
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.